These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31895187)

  • 21. Experiences with medical cannabis in the treatment of veterans with PTSD: Results from a focus group discussion.
    Krediet E; Janssen DG; Heerdink ER; Egberts TC; Vermetten E
    Eur Neuropsychopharmacol; 2020 Jul; 36():244-254. PubMed ID: 32576481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The Clinical Toxicology Perspective on the Therapeutic Use of Cannabis and Cannabinoids].
    Dinis-Oliveira RJ
    Acta Med Port; 2019 Feb; 32(2):87-90. PubMed ID: 30896388
    [No Abstract]   [Full Text] [Related]  

  • 23. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.
    Papini S; Sullivan GM; Hien DA; Shvil E; Neria Y
    Biol Psychol; 2015 Jan; 104():8-18. PubMed ID: 25448242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.
    Passie T; Emrich HM; Karst M; Brandt SD; Halpern JH
    Drug Test Anal; 2012; 4(7-8):649-59. PubMed ID: 22736575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Construct of Medical and Non-Medical Marijuana-Critical Review.
    Silczuk A; Smułek D; Kołodziej M; Gujska J
    Int J Environ Res Public Health; 2022 Feb; 19(5):. PubMed ID: 35270462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective.
    Ney LJ; Akosile W; Davey C; Pitcher L; Felmingham KL; Mayo LM; Hill MN; Strodl E
    Expert Rev Clin Pharmacol; 2023; 16(11):1093-1108. PubMed ID: 37885234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans.
    Chadwick VL; Rohleder C; Koethe D; Leweke FM
    Curr Opin Psychiatry; 2020 Jan; 33(1):20-42. PubMed ID: 31714262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical marijuana: Showdown at the cannabis corral.
    Eisenstein M
    Nature; 2015 Sep; 525(7570):S15-7. PubMed ID: 26398734
    [No Abstract]   [Full Text] [Related]  

  • 29. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
    Turna J; Patterson B; Van Ameringen M
    Depress Anxiety; 2017 Nov; 34(11):1006-1017. PubMed ID: 28636769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between substance use and posttraumatic stress disorder in a methadone maintenance treatment program.
    Villagonzalo KA; Dodd S; Ng F; Mihaly S; Langbein A; Berk M
    Compr Psychiatry; 2011; 52(5):562-6. PubMed ID: 21109242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTSD and substance use disorder among veterans: characteristics, service utilization and pharmacotherapy.
    Bowe A; Rosenheck R
    J Dual Diagn; 2015; 11(1):22-32. PubMed ID: 25513763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the endocannabinoid system to treat anxiety-related disorders.
    Korem N; Zer-Aviv TM; Ganon-Elazar E; Abush H; Akirav I
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):193-202. PubMed ID: 26426887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis.
    Coventry PA; Meader N; Melton H; Temple M; Dale H; Wright K; Cloitre M; Karatzias T; Bisson J; Roberts NP; Brown JVE; Barbui C; Churchill R; Lovell K; McMillan D; Gilbody S
    PLoS Med; 2020 Aug; 17(8):e1003262. PubMed ID: 32813696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive and Negative Effects of Cannabis and Cannabinoids on Health.
    Cohen K; Weizman A; Weinstein A
    Clin Pharmacol Ther; 2019 May; 105(5):1139-1147. PubMed ID: 30703255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical Cannabis and Psychiatric Disorders: Implications for Psychiatric Nurses.
    Groh CJ
    J Am Psychiatr Nurses Assoc; 2022; 28(1):91-103. PubMed ID: 32772621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to prescription guidelines for medical cannabis in disability claimants.
    Elias DA; MacLaren VV; Hill-Elias R; Metcalfe AWS
    Can Fam Physician; 2019 Aug; 65(8):e339-e343. PubMed ID: 31413039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic management of comorbid post-traumatic stress disorder and addictions.
    Shorter D; Hsieh J; Kosten TR
    Am J Addict; 2015 Dec; 24(8):705-12. PubMed ID: 26587796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabinoids: Medical implications.
    Schrot RJ; Hubbard JR
    Ann Med; 2016; 48(3):128-41. PubMed ID: 26912385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactive effects of PTSD and substance use on suicidal ideation and behavior in military personnel: Increased risk from marijuana use.
    Allan NP; Ashrafioun L; Kolnogorova K; Raines AM; Hoge CW; Stecker T
    Depress Anxiety; 2019 Nov; 36(11):1072-1079. PubMed ID: 31475423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of co-occurring addictions, posttraumatic stress disorder, and major depressive disorder in detoxification treatment seekers: Implications for improving detoxification treatment outcomes.
    Anderson RE; Hruska B; Boros AP; Richardson CJ; Delahanty DL
    J Subst Abuse Treat; 2018 Mar; 86():45-51. PubMed ID: 29415850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.